GO
| HSI1 | 24,917.60 | +111.97 | 192.63B |
| HSCEI1 | 8,284.58 | +38.25 | 51.08B |
| Back Zoom + Zoom - Block Traded | |
|
2026-09-14 17:07:33 BofAS published a research report stating that AKESO (09926.HK)'s HARMONi-2 study delivered encouraging overall survival (OS) benefits, with a hazard ratio (HR) of 0.73. The broker maintained its Buy rating. The broker noted that ivonescimab's robust trial data in China provides a strong reference for global clinical trial results. The company is entering a pivotal 2026, with important data readouts expected from global and China Phase III programs, while accelerating commercialization momentum in China. Its extensive pipeline also offers long-term growth and new out-licensing opportunities. Using a discounted cash flow (DCF) model, the broker set a target price of HKD136. Downside risks include uncertainties surrounding ivonescimab's future clinical results and regulatory timelines, intensifying global competition, and potential pricing pressure from the National Reimbursement Drug List and US price cuts. Upside risks include better-than-expected clinical results, new out-licensing deals, and product sales exceeding expectations. (su/ad)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |